Nuvation Bio Inc.
NYSE:NUVBBiotechnology
+$0.06 today
- Market cap
- $1.33B
- Beta
- 1.56
- P/E (TTM)
- -12.8
- EPS (TTM)
- -$0.42
Volume 5.96M
Average 4.07M
NUVB EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
Nuvation Bio Inc.NYSE: NUVB
EPS (Basic) · Q2 FY2026 · quarter ended Jun 2026
EPS (Basic) remains negative
Q2 FY2026 EPS (Basic) was -$0.18, compared with -$0.17 a year earlier. Trailing-twelve-month EPS (Basic) was -$0.43.
Context
- EPS (Basic) grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EPS (Basic) reaches the consensus estimate from 7 analysts of -$0.4 (+33.0%) for the fiscal year ending Dec 2026, a slowdown from the +71.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$0.18-1261.3% QoQ
- Last fiscal yearDec 2025
- -$0.6+71.6% YoY
- LTMJun 2026
- -$0.43+31.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -5.9% | +22.7% | +28.5 pp |
| 1 year | +71.6% | +33.0% | -38.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Basic) history
USD · from the income statement
- Latest · FY2025
- (0.60) USD
- Year-over-year change
- +71.6%
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (0.60) | +71.6% |
| FY2024 | 2024-12-31 | (2.11) | -502.9% |
| FY2023 | 2023-12-31 | (0.35) | +27.1% |
| FY2022 | 2022-12-31 | (0.48) | -9.1% |
| FY2021 | 2021-12-31 | (0.44) | — |
EPS (Basic) vs competitors
How NUVB compares with its peers on the latest reported figures
- NUVB's LTM Jun 2026 EPS (Basic) of -$0.43 is the 3rd highest of the 11 companies compared; the peer median is -$2.44.
- Its year-over-year change of +31.0% is the 3rd highest of 11, against a peer median of +8.0%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | $9.25 | +685.4% | — | |
| LTM Jun 2026 | $2.36 | +448.8% | — | |
| LTM Jun 2026 | -$0.43 | +31.0% | — | |
| LTM Sep 2026 | -$0.48 | +17.2% | — | |
| LTM Mar 2026 | -$1.46 | -27.0% | — | |
| LTM Mar 2026 | -$1.84 | -35.3% | — | |
| LTM Jun 2026 | -$3.03 | +2.9% | — | |
| LTM Mar 2026 | -$3.51 | +20.0% | — | |
| LTM Jun 2026 | -$3.53 | +13.1% | — | |
| LTM Sep 2026 | -$4.31 | -27.5% | — | |
| LTM Jun 2026 | -$5.86 | -58.0% | — | |
| Peer median (excluding NUVB) | -$2.44 | +8.0% | — | |
Competitors are the stored peer set for NUVB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 7.87M | 62.9M |
| Cost of Revenue | 0 | 0 | 0 | 7.08M | 8.44M |
| Gross Profit | 0 | 0 | 0 | 795K | 54.46M |
| Gross Margin | — | — | — | 10.1% | 86.6% |
| Research & Development | 69.04M | 87.82M | 71.29M | 524.19M | 115.11M |
| Selling, General & Admin | 24.28M | 31.92M | 28.53M | 69.23M | 151.56M |
| Operating Expenses | 93.32M | 119.73M | 99.82M | 593.42M | 267.52M |
| Depreciation & Amortization | 184K | 199K | 222K | 683K | 1.74M |
| EBITDA | (86.66M) | (104M) | (75.58M) | (566.92M) | (189.21M) |
| EBITDA Margin | — | — | — | -7200.7% | -300.8% |
| Operating Income | (93.32M) | (119.73M) | (99.82M) | (592.63M) | (213.06M) |
| Operating Margin | — | — | — | -7527.3% | -338.7% |
| Interest Income | 2.96M | 7.45M | 24.61M | 27.06M | 21.43M |
| Interest Expense | 0 | 0 | 0 | 341K | 13.68M |
| Other Income / Expenses | 6.47M | 15.54M | 24.02M | 24.69M | 8.44M |
| Income Before Tax | (86.85M) | (104.2M) | (75.8M) | (567.94M) | (204.63M) |
| Pre-Tax Margin | — | — | — | -7213.8% | -325.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (86.85M) | (104.2M) | (75.8M) | (567.94M) | (204.63M) |
| Net Margin | — | — | — | -7213.8% | -325.3% |
| EPS (Basic) | (0.44) | (0.48) | (0.35) | (2.11) | (0.60) |
| EPS (Diluted) | (0.44) | (0.48) | (0.35) | (2.11) | (0.60) |
| Weighted Avg Shares | 197.89M | 216.72M | 218.88M | 268.77M | 341.54M |
| Weighted Avg Shares (Diluted) | 197.89M | 216.72M | 218.88M | 268.77M | 341.54M |
Nuvation Bio Inc.
NYSE:NUVB
Intrinsic Alpha fair value
Locked
Current Price
$3.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.